Lee, J. C., J.-Y. Hung, Y.-C. Kim, G.-C. Chang, S. Yoo, S.-H. Yang, K. Davis, S. Nagar, A. Taylor, S. Lee, and J.-Y. Shih. “Real-World Treatment Patterns in Patients With EGFR Mutation-Positive NSCLC Receiving a First-Line, First- or Second-Generation EGFR Tyrosine Kinase Inhibitor in South Korea and Taiwan”. Asian Pacific Journal of Cancer Biology, Vol. 6, no. 2, May 2021, pp. 123-32, doi:10.31557/apjcb.2021.6.2.123-132.